The Fundamental and Clinical Medicine journal published the results of a study on laboratory animals on the effectiveness of replacing bone defects using the Russian medical product Bongraf COLLAGEN. The product has the working name of Bongraf, and is produced under the Matriflex umbrella brand.
The experiments were carried out by a group of scientists from the Honorary Academician N. F. Gamaleya National Research Center for Epidemiology and Microbiology under the Ministry of Health of Russia, the Lomonosov Moscow State University, and the Nearmedic group in order to evaluate the effectiveness of replacing bone defects using xenogenic native non-reconstructed bone collagen in comparison to other widely used solutions.
The study involved 48 male Wistar or Sprague-Dawley rats possessing mature bone skeletons. During surgery, a bone defect was created, and then the defect cavity was filled with Bongraf COLLAGEN medical product, its foreign analog Geistlich Bio-Oss ® , a bone autograft (a removed section of the test rat’s skull bone), or left unfilled. After 4 or 12 weeks from the moment of creating the defect, some of the animals were removed from the experiment and the replacement of the defect with bone tissue was studied using microcomputer tomography.
As a result of the experiment, it was found that rats whose bone defect had been filled with the Bongraf COLLAGEN product, demonstrated a pronounced tendency to regenerate over time. When using the Bongraf COLLAGEN product, by the 12th week after implantation, the volume of newly formed bone tissue in the defect lumen and the proportion of bone tissue to the defect lumen were not lower than those achieved with the use of the Geistlich Bio-Oss ® product widely used in clinical practice nowadays.
«The data obtained suggest that the Russian Bongraf COLLAGEN is comparable in efficiency to the Swiss-made Geistlich Bio-Oss ® bone substitute, meaning that it can be an alternative to foreign products on the domestic market,» says Alexey Veremeev, head of the Medical Products sector of the Nearmedic group.
«Improving the effectiveness and reducing the time of rehabilitation after surgery on the musculoskeletal system is an important medical task. According to the TECHART marketing group, the annual demand for bone implants in our country ranges between 150 and 275 thousand pieces. At the same time, due to the limited possibilities of using bone autografts, when the recipient of the transplant is a donor to himself, as well as the insufficient effectiveness of allotransplants, when bone tissue is taken from another person, modern science is focused on the development of various bone substitutes. Bongraf COLLAGEN is one of the most promising bone substitutes for use in Russian clinical practice due to its proven effectiveness and lower cost compared to Western analogues,» said Alexander Nenyukov, CEO of the BioPHARMAHOLDING LLC.
Production of a line of bone substitutes is planned to be launched in 2021 on the basis of BioPHARMAHOLDING LLC which is part of the Nearmedic group of companies. Serial products will be produced under the Matriflex® trademark.
Bongraf COLLAGEN is an original product developed by the Matriflex LLC, a Russian company (part of the Nearmedic group of companies), and presents a cell-free bone collagen which is obtained from bovine thighbone and subjected to a multi-stage purification process employing the OnIonTech unique technology. The material has a porous structure, very similar to the structure of autogenous bone, and, gradually resorbing, it is replaced by the new bone tissue. It is used in traumatology, orthopedics, and dentistry to replace bone defects. The product has the working name of Bongraf and is produced under the Matriflex umbrella brand.
Fundamental and Clinical Medicine is a quarterly science and practice peer-reviewed journal that publishes results of domestic and foreign scientific research in the field of fundamental medical science and clinical practice, preventive medicine, new medical technologies and education. All articles of the journal are subjected to blind double peer-reviewing and placed in open access in the Scientific Electronic Library.
The Nearmedic group is a Russian pharmaceutical, biotechnological and medical company that specializes, among other things, in the production of diagnostic test systems, other medical products, and medicines, and their introduction into medical practice. At the company’s plant, all technological processes, starting with the synthesis of raw materials and to the manufacture of finished preparations and reagent kits, are carried out in the framework of one production facility.